Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-30 @ 12:16 AM
Study NCT ID:
NCT07407803
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-02-12
First Post:
2026-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D018318', 'term': 'Neurofibroma, Plexiform'}], 'ancestors': [{'id': 'D009455', 'term': 'Neurofibroma'}, {'id': 'D018317', 'term': 'Nerve Sheath Neoplasms'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D010524', 'term': 'Peripheral Nervous System Neoplasms'}, {'id': 'D009423', 'term': 'Nervous System Neoplasms'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 177}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-02', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2028-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-02-10', 'studyFirstSubmitDate': '2026-02-03', 'studyFirstSubmitQcDate': '2026-02-10', 'lastUpdatePostDateStruct': {'date': '2026-02-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-02-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'IRC-Assessed Objective Response Rate (ORR)', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by independent review committee (IRC) per REiNS criteria at the end of Cycle 24.'}], 'secondaryOutcomes': [{'measure': 'Investigator-Assessed ORR', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by investigators per REiNS criteria.'}, {'measure': 'IRC/Investigator-Assessed DOR', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Duration of response (DOR), defined as the time from first documented confirmed objective response to disease progression or death from any cause (whichever occurs first), as determined by IRC/investigators per REiNS criteria.'}, {'measure': 'IRC/Investigator-Assessed disease control rate (DCR)', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Percentage of subjects achieving complete response (CR), partial response (PR), or stable disease (SD) as determined by IRC/investigators per REiNS criteria.'}, {'measure': 'IRC/Investigator-Assessed progression-free survival (PFS )', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Time from randomization to first disease progression or death from any cause (whichever occurs first), as determined by IRC/investigators per REiNS criteria.'}, {'measure': 'IRC/Investigator-Assessed TTP', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Time from randomization to first disease progression (TTP), as assessed by IRC/investigators per REiNS criteria.'}, {'measure': 'IRC/Investigator-Assessed time to response (TTR)', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Time from randomization to first objective response, as determined by IRC/investigators per REiNS criteria.'}, {'measure': 'Tumor response in subject', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Difference in the best percentage change from baseline in target PN volume between groups, as assessed by IRC/investigators.'}, {'measure': 'Number of subjects with incidence and severity of adverse events (AEs)', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Incidence and severity of adverse events from subject enrollment to the end of cycle 24.'}, {'measure': 'Patient-reported outcomes', 'timeFrame': 'From subject enrollment to the end of cycle 24 (each cycle is 28 days)', 'description': 'Patient self-assessment results from subject enrollment to the end of cycle 24.'}, {'measure': 'Peak concentration (Cmax)', 'timeFrame': '2 hours after administration', 'description': 'Maximum plasma drug concentration'}, {'measure': 'Plasma concentration at steady state (Ctrough, SS)', 'timeFrame': 'Cycle 1 day 28: pre-dose, Cycle 2 day 28 pre-dose, Cycle 3 day 28: pre-dose, Cycle 6 day 28: pre-dose. (each cycle is 28 days)', 'description': 'The pre-dose concentration observed when the drug has reached steady state with repeated dosing, indicating baseline exposure and accumulation.'}, {'measure': 'Effects on pain score in subjects', 'timeFrame': 'From subject enrollment to the end of the 24th cycle (each cycle is 28 days)', 'description': 'Questionnaire: Numerical Rating Scale-11 (NRS-11); The line segments below all have numbers from 0 to 10, where 0 means no pain and 10 is the worst pain you can imagine.'}, {'measure': 'Effects on pain interference index in subjects', 'timeFrame': 'From subject enrollment to the end of the 24th cycle (each cycle is 28 days)', 'description': 'Questionnaire: pain interference index; Please answer each one by circling a number from 0 to 6, where 0 means none at all and 6 means completely'}, {'measure': "Effects on subjects' general quality of life", 'timeFrame': 'From subject enrollment to the end of the 24th cycle (each cycle is 28 days)', 'description': 'Questionnaire: Functional Assessment of Cancer Therapy - General (FACT-G); the scores from all items across its four domains are summed to obtain a total score, which ranges from 0 to 108 points.'}, {'measure': 'Effects on subjects; disease-specific quality of life', 'timeFrame': 'From subject enrollment to the end of the 24th cycle (each cycle is 28 days)', 'description': 'Questionnaire: PedsQL NF1 Module; It includes an Adult version (\\>25 years) and a Young Adult version (18-25 years), with 104 items, respectively.'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Plexiform Neurofibroma']}, 'descriptionModule': {'briefSummary': 'This study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24 compared to placebo.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* The subject voluntarily joins this study, signs the informed consent form, and demonstrates good compliance.\n* Age ≥18 years (calculated from the date of signing the informed consent form).\n* Diagnosis of symptomatic, non-resectable neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN) requiring systemic therapy per investigator judgment.\n* At least one measurable lesion with a dimension ≥3 cm.\n* There should be no significant changes in the use of chronic neuropathic pain medications within 28 days prior to study enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Laboratory tests meet the protocol criteria.\n* Women of childbearing potential must agree to use effective contraception during the study and for 6 months after study completion. A negative serum pregnancy test must be documented within 7 days prior to study enrollment. Men must agree to use effective contraception during the study and for 6 months after study completion.\n\nExclusion Criteria:\n\n* Confirmed or suspected malignant glioma or malignant peripheral nerve sheath tumor (MPNST) (excluding low-grade glioma, optic nerve glioma not requiring systemic therapy or radiotherapy); histological confirmation may be required.\n* History of or concurrent other malignancies within 5 years prior to first dosing.\n* Multiple factors affecting oral drug absorption (e.g., dysphagia, chronic diarrhea, intestinal obstruction, major bowel resection).\n* Adverse reactions from prior anti-tumor therapy not recovered to NCI CTCAE v6.0 grade ≤1, except grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non-clinically significant and asymptomatic laboratory abnormalities, and hypothyroidism stabilized by hormone replacement therapy.\n* Major surgery, significant traumatic injury, or planned major surgery during the study within 4 weeks prior to first dosing; or presence of long-term non-healed wounds or fractures.\n* History of arterial/venous thrombotic events (e.g., cerebrovascular accident including transient ischemic attack (TIA), deep vein thrombosis, pulmonary embolism) or other severe thromboembolic events within 6 months prior to first dosing.\n* Active viral hepatitis with poor control.\n* Active syphilis requiring treatment.\n* Active tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia.\n* History of substance abuse that cannot be controlled or presence of psychiatric disorders.\n* Planned or prior allogeneic bone marrow or solid organ transplantation.\n* History of hepatic encephalopathy.\n* History of or current retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), central serous retinopathy (CSR), glaucoma, or other significant ocular abnormalities (e.g., intraocular pressure \\>21mmHg).\n* Inability to undergo MRI and/or presence of MRI contraindications.\n* Major cardiovascular disease.\n* Active or uncontrolled severe infection.\n* Renal failure requiring hemodialysis or peritoneal dialysis.\n* History of immunodeficiency, including HIV-positive or other acquired/congenital immunodeficiency diseases.\n* History of epilepsy.\n* Tumor-related symptoms and treatment.\n* Known hypersensitivity to study drug excipients.\n* Participation in and use of other PN clinical trial drugs within 4 weeks prior to first dosing.\n* Pregnant or lactating participants.\n* Any other condition that, in the investigator's judgment, poses a serious risk to participant safety or interferes with study completion."}, 'identificationModule': {'nctId': 'NCT07407803', 'briefTitle': 'Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas', 'organization': {'class': 'INDUSTRY', 'fullName': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'}, 'officialTitle': 'Randomized, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas', 'orgStudyIdInfo': {'id': 'TQ-B3234-III-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'TQ-B3234 capsules', 'description': 'TQ-B3234 capsules: 50 mg once daily, one cycle every 4 weeks (28 days)', 'interventionNames': ['Drug: TQ-B3234 capsules']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'TQ-B3234 placebo', 'description': 'TQ-B3234 placebo: 0 mg once daily, one cycle every 4 weeks (28 days)', 'interventionNames': ['Drug: TQ-B3234 placebo']}], 'interventions': [{'name': 'TQ-B3234 capsules', 'type': 'DRUG', 'description': 'TQ-B3234 is an antitumor molecular targeted drug, a selective mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor. It primarily inhibits the mitogen-activated protein kinase (MEK) protein (an upstream regulator of the extracellular signal-regulated kinase (ERK) pathway), thereby affecting the mitogen-activated protein kinase (MAPK) pathway and suppressing cell proliferation. MEK inhibitors are recognized to play a significant role in the pathogenesis of plexiform neurofibromas associated with neurofibromatosis type 1.', 'armGroupLabels': ['TQ-B3234 capsules']}, {'name': 'TQ-B3234 placebo', 'type': 'DRUG', 'description': 'TQ-B3234 placebo without drug substance.', 'armGroupLabels': ['TQ-B3234 placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '230000', 'city': 'Hefei', 'state': 'Anhui', 'country': 'China', 'contacts': [{'name': 'Beicheng Sun, Doctor', 'role': 'CONTACT', 'email': 'sunbc0207@163.com', 'phone': '13776413940'}], 'facility': 'The First Affiliated Hospital of Anhui Medical University', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'zip': '100032', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'contacts': [{'name': 'Xiao Long, Doctor', 'role': 'CONTACT', 'email': 'pumclongxiao@126.com', 'phone': '13810193175'}], 'facility': 'Peking Union Medical College Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100032', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'contacts': [{'name': 'Qingtang Lin, Doctor', 'role': 'CONTACT', 'email': 'kingsang2002@hotmail.com', 'phone': '15801588169'}], 'facility': 'Xuanwu Hospital Capital Medical University', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100070', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'contacts': [{'name': 'Bo Wang, Doctor', 'role': 'CONTACT', 'email': 'docking@163.com', 'phone': '13811713730'}], 'facility': 'Beijing Tiantan Hospital, Capital Medical University', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100083', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'contacts': [{'name': 'Liping Wang, Doctor', 'role': 'CONTACT', 'email': 'dianen@126.com', 'phone': '13810002694'}], 'facility': 'Peking University Third Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '400000', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'country': 'China', 'facility': 'The Southwest Hospital of Amu', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '350004', 'city': 'Fuzhou', 'state': 'Fujian', 'country': 'China', 'contacts': [{'name': 'Yuanxiang Lin, Doctor', 'role': 'CONTACT', 'email': 'lyx99070@163.com', 'phone': '13906918894'}], 'facility': 'The First Affiliated Hospital of Fujan Medical University', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'zip': '730050', 'city': 'Lanzhou', 'state': 'Gansu', 'country': 'China', 'contacts': [{'name': 'Jing Li, Bachelor', 'role': 'CONTACT', 'email': '1368406388@qq.com', 'phone': '13321229317'}], 'facility': 'Gansu Provincial Cancer Hospital', 'geoPoint': {'lat': 36.05701, 'lon': 103.83987}}, {'zip': '510060', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'contacts': [{'name': 'Zhongping Chen, Doctor', 'role': 'CONTACT', 'email': 'chenzhp@sysucc.org.cn', 'phone': '13500002457'}], 'facility': 'Sun Yat-Sen University Cancer Center', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '510091', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'contacts': [{'name': 'Zhimiao Lin, Doctor', 'role': 'CONTACT', 'email': 'zhimiaolin@126.com', 'phone': '13681438841'}], 'facility': 'Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital / Guangdong Center for the Prevention and Control of Sexually Transmitted Diseases and Leprosy', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '530021', 'city': 'Nanning', 'state': 'Guangxi', 'country': 'China', 'contacts': [{'name': 'Ligen Mo, Doctor', 'role': 'CONTACT', 'email': 'ligenmo@163.com', 'phone': '13807816094'}], 'facility': 'Guangxi Medical University Cancer Hospital （ Guangxi Cancer InstituteGuangxi Cancer Hospital & Medical University Oncology School & Cancer Center）', 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'zip': '550002', 'city': 'Guiyang', 'state': 'Guizhou', 'country': 'China', 'contacts': [{'name': 'DEYI ZHENG, Doctor', 'role': 'CONTACT', 'email': 'deyizheng@126.com', 'phone': '139 8482 6262'}], 'facility': "Guizhou Provincial People's Hospital", 'geoPoint': {'lat': 26.58333, 'lon': 106.71667}}, {'zip': '05000', 'city': 'Shijiazhuang', 'state': 'Hebei', 'country': 'China', 'contacts': [{'name': 'Yanling Li, Doctor', 'role': 'CONTACT', 'email': 'lyldoctor@sina.com', 'phone': '15130119920'}], 'facility': 'The second hospital of Hebei medical university', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}}, {'zip': '471000', 'city': 'Luoyang', 'state': 'Henan', 'country': 'China', 'contacts': [{'name': 'Ying Yao, Doctor', 'role': 'CONTACT', 'email': '15537990507@163.com', 'phone': '15537990507'}], 'facility': 'The Second Affiliated Hospital of Henan University of Science and Technology', 'geoPoint': {'lat': 34.67345, 'lon': 112.43684}}, {'zip': '450000', 'city': 'Zhengzhou', 'state': 'Henan', 'country': 'China', 'contacts': [{'name': 'Guangshuai Li, Doctor', 'role': 'CONTACT', 'email': 'liguangshuai@zzu.edu.cn', 'phone': '13838062386'}], 'facility': 'The First Affiliated Hospital Of Zhengzhou University', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '42000', 'city': 'Wuhan', 'state': 'Hubei', 'country': 'China', 'contacts': [{'name': 'Shan Jiang, Doctor', 'role': 'CONTACT', 'email': 'Jiangshan794101@126.com', 'phone': '13659892065'}], 'facility': 'Renmin Hospital of Wuhan University(Hubei General Hospital)', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '410007', 'city': 'Changsha', 'state': 'Hunan', 'country': 'China', 'contacts': [{'name': 'Liwen Wu, Doctor', 'role': 'CONTACT', 'email': 'hnsetyysjnk168@163.com', 'phone': '137872458'}], 'facility': "Hunan Children's Hospital", 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'zip': '210008', 'city': 'Nanjing', 'state': 'Jiangsu', 'country': 'China', 'facility': 'Nanjing Drum Tower Hospital', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '110801', 'city': 'Shenyang', 'state': 'Liaoning', 'country': 'China', 'contacts': [{'name': 'Xinghua Gao, Doctor', 'role': 'CONTACT', 'email': 'gaobarry@hotmail.com', 'phone': '13940152467'}], 'facility': 'The First Affiliated Hospital of China Medical University', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}, {'zip': '710000', 'city': "Xi'an", 'state': 'Shaanxi', 'country': 'China', 'contacts': [{'name': 'Baoqiang Song, Doctor', 'role': 'CONTACT', 'email': 'songbq1@163.com', 'phone': '18829025566'}], 'facility': 'Xijing hospital', 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}, {'zip': '250012', 'city': 'Jinan', 'state': 'Shandong', 'country': 'China', 'contacts': [{'name': 'Shilei Ni, Doctor', 'role': 'CONTACT', 'email': 'nishilei@sdu.edu.cn', 'phone': '13869196590'}], 'facility': 'Qilu Hospital of Shandong University', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '250012', 'city': 'Jinan', 'state': 'Shandong', 'country': 'China', 'contacts': [{'name': 'Aijun Zhang, Doctor', 'role': 'CONTACT', 'email': 'zhangaijun@sdu.edu.cn', 'phone': '18560086212'}], 'facility': 'Qilu Hospital of Shandong University', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '200011', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'contacts': [{'name': 'Qingfeng Li, Doctor', 'role': 'CONTACT', 'email': 'dr.liqingfeng@shsmu.edu.cn', 'phone': '021 53315108'}], 'facility': "Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine", 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '030000', 'city': 'Taiyuan', 'state': 'Shanxi', 'country': 'China', 'facility': 'Shanxi Cancer Hospital', 'geoPoint': {'lat': 37.86944, 'lon': 112.56028}}, {'zip': '610041', 'city': 'Chengdu', 'state': 'Sichuan', 'country': 'China', 'contacts': [{'name': 'Yange Zhang, Doctor', 'role': 'CONTACT', 'email': 'zhangyange7801@163.com', 'phone': '15882307640'}], 'facility': 'West China Hospital, Sichuan University', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '610072', 'city': 'Chengdu', 'state': 'Sichuan', 'country': 'China', 'contacts': [{'name': 'Yaqiu Wu, Bachelor', 'role': 'CONTACT', 'email': 'wuyaqiu829@163.om', 'phone': '13551213719'}], 'facility': "Sichuan Academy of Medical Science&Sichuan Provincial People' Hospital", 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '300000', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'country': 'China', 'contacts': [{'name': 'Jilong Yang, Doctor', 'role': 'CONTACT', 'email': 'yangjilong@tjmuch.com', 'phone': '18622221626'}], 'facility': 'Tianjin Medical University Cancer Institute & Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '650000', 'city': 'Kunming', 'state': 'Yunnan', 'country': 'China', 'contacts': [{'name': 'YANG TANG, Doctor', 'role': 'CONTACT', 'email': 'drtangyang@126.com', 'phone': '13518780688'}], 'facility': 'The First Affiliated Hospital Of Kunming Medical University', 'geoPoint': {'lat': 25.03889, 'lon': 102.71833}}, {'zip': '310014', 'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'contacts': [{'name': 'Shuofan Wu, Doctor', 'role': 'CONTACT', 'email': 'sufanwu@163.com', 'phone': '13857121888'}], 'facility': "Zhejiang Provincial People'S Hospital", 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}], 'centralContacts': [{'name': 'Qingfeng Li, Doctor', 'role': 'CONTACT', 'email': 'dr.liqingfeng@shsmu.edu.cn', 'phone': '021 53315108'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}